SYNCOM FORMULATIONS (INDIA)
|
|
BOM : 524470     NSE : SYNCOMF     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Nov 01,2024 |
Price(EOD): ₹ 20.83
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 1,958.02 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SYNCOM FORMULATIONS (INDIA) | 6.7% | -2.3% | 140.6% |
SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -2.9% | 69.8% |
CIPLA | 3.7% | -5.9% | 29.5% |
DR REDDYS LABORATORIES | -4.1% | -6.6% | 18.8% |
ZYDUS LIFESCIENCES | -0.3% | -6.1% | 74.6% |
DIVIS LABORATORIES | 1.6% | 8.7% | 74% |
MANKIND PHARMA | 10.8% | 6.3% | 53.2% |
TORRENT PHARMACEUTICALS | -3.2% | -5.4% | 66.1% |
LUPIN | -0.3% | 0.7% | 93.8% |
FUNDAMENTAL ANALYSIS OF SYNCOM FORMULATIONS (INDIA)
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SYNCOM FORMULATIONS (INDIA)
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
68.58
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 28.55 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 6.8
P/B Calculated based on Book Value of Rs 288.14 Cr
[Latest Year - Mar2024 - Consolidated Results ] 6.73
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 290.81 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
444% 150% 154% |
SHARE PRICE MOMENTUM OF SYNCOM FORMULATIONS (INDIA)
SYNCOM FORMULATIONS (INDIA) vs SENSEX
DEBT OF SYNCOM FORMULATIONS (INDIA)
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.25 0.32 0.27 0.28 |
0.25 0.32 0.27 0.28 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SYNCOM FORMULATIONS (INDIA)
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SYNCOM FORMULATIONS (INDIA)
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
17.01% 10.93% 0.74% 3.11% |
45.82% 61.83% 65.3% 73.64% |
QtrlyTrend |
8 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
SYNCOM FORMULATIONS (INDIA) related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | 6.3% | -3.2% | 50.7% |
S&P BSE MIDSMALLCAP | 4.1% | -4.8% | 49.7% |
S&P BSE HEALTHCARE | 3% | -0.4% | 61% |
S&P BSE ALLCAP | 1.8% | -5.8% | 36% |
You may also like the below Video Courses
FAQ about SYNCOM FORMULATIONS (INDIA)
Is SYNCOM FORMULATIONS (INDIA) good for long term investment?
As on Nov 01,2024, the Fundamentals of SYNCOM FORMULATIONS (INDIA) look Strong and hence it may be good for long term investment! See Financial Performance of SYNCOM FORMULATIONS (INDIA) . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SYNCOM FORMULATIONS (INDIA) UnderValued or OverValued?
As on Nov 01,2024, SYNCOM FORMULATIONS (INDIA) is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SYNCOM FORMULATIONS (INDIA) ?
As on Nov 01,2024, the Intrinsic Value of SYNCOM FORMULATIONS (INDIA) is Rs. 8.20 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 3.83
Fair Value [Median EV / Sales Model] : Rs. 8.34
Fair Value [Median Price / Sales Model] : Rs. 8.20
Estimated Median Fair Value of SYNCOM FORMULATIONS (INDIA) : Rs. 8.20
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.